Hospital Adds Accuray ClearRT™ Helical
Fan-Beam kVCT Imaging and Synchrony® Technologies to
Both Radixact Systems, Creating the Ultimate System for
Personalized Cancer Care
SUNNYVALE, Calif., Nov. 16,
2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ:
ARAY) announced today that the Oscar Lambret Center in Lille, France has installed its second
Radixact® System and the hospital's fifth Accuray
radiation therapy delivery system. The hospital has enhanced both
Radixact Systems with the addition of the Accuray-only ClearRT™
Helical Fan-Beam kVCT Imaging and
Synchrony® technologies, applications designed to
improve treatment outcomes and versatility in the types of diseases
that can be treated.
ClearRT integrated with Synchrony on the Radixact
System provides the tools to increase the precision and
accuracy of treatments and as a result, expands the type of
external beam radiation therapy that can be delivered with one
system. From extremely precise and accurate conventionally
fractionated image-guided intensity-modulated radiation therapy
(IG-IMRT) to ultra-hypofractionated stereotactic body radiation
therapy (SBRT) treatments, the care team has the flexibility to
choose the modality that is most appropriate for each patient based
on a range of factors including their medical condition and
history, age and lifestyle.
"We value our long-standing relationship with the Oscar Lambret
team and look forward to partnering with them for many years to
come. I believe Accuray technologies support the hospital's
patient-focused mission and will enable them to achieve the highest
levels of cancer care while increasing the number of people within
their community who can be helped on a daily basis," said
Suzanne Winter, president and CEO of
Accuray.
The Oscar Lambret Center is part of Unicancer, the only French
hospital network dedicated 100% to cancer care, research and
education. The hospital, in operation for more than 65 years, has
pioneered the use of numerous diagnosis and treatment modalities to
improve the care of their patients. The medical care team is a
long-term user of Accuray technology, having treated their first
patients with the Accuray CyberKnife® System in
2007. The team continued its legacy of innovation in 2013 when they
treated the first patient in the world with the TomoHDA™
System.
"The Oscar Lambret Center is recognized for its scientific and
technical expertise. We are dedicated to providing personalized,
high-quality cancer care based on the latest research and most
advanced treatment options, such as the Radixact System with
ClearRT and Synchrony," said Xavier
Mirabel, M.D., head of the radiation therapy department,
Oscar Lambret Center. "The technologies offer many benefits
including the ability to see tumors more clearly and target them
more precisely by adapting to tumor or patient motion."
The Oscar Lambret team selected the Radixact System, the latest
generation of the TomoTherapy® platform, with ClearRT
and Synchrony to offer their patients even more precise radiation
therapy treatments on a daily basis and improve the patient
experience. The system provides an option for almost any tumor that
would benefit from radiation therapy, including those that move,
and will be the hospital's primary device for the treatment of
cancer in the head and neck and pelvis.
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions that are designed to deliver
radiation treatments for even the most complex cases—while making
commonly treatable cases even easier—to meet the full spectrum of
patient needs. We are dedicated to continuous innovation in
radiation therapy for oncology, neuro-radiosurgery, and beyond, as
we partner with clinicians and administrators, empowering them to
help patients get back to their lives, faster. Accuray is
headquartered in Sunnyvale,
California, with facilities worldwide. To learn more, visit
www.accuray.com or follow us on Facebook, LinkedIn,
Twitter, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and patient outcomes. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products, including new product
innovations and releases; the company's ability to develop new
products or improve existing products to meet customers' needs; the
company's ability to anticipate or keep pace with changes in the
marketplace; and the direction of technological innovation and
customer demands and such other risks identified under the heading
"Risk Factors" in the company's Quarterly Report on Form 10-Q,
filed with the Securities and Exchange Commission (the "SEC") on
November 3, 2022, and as updated
periodically with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/oscar-lambret-center-in-france-installs-second-accuray-radixact-system-the-hospitals-fifth-accuray-radiation-therapy-delivery-system-301679704.html
SOURCE Accuray Incorporated